Sionna Q2 Loss Widens to $29.9M; Cash Runway into 2028, Key Data Readouts This Summer
SION has more than doubled off its 52-week low of $16.48.
Summary
Sionna reported a wider Q2 loss of $29.9M, guided cash runway into 2028, and confirmed two key clinical data readouts this summer. A $250M ATM program is in place but unused.
Key Events · Earnings and Guidance · SION
-
Q2 Net Loss Widens
Net loss of $29.9M vs $18.1M in Q2 2025, driven by a $6.5M increase in R&D expenses to $21.9M as clinical programs advance.
-
Cash Runway into 2028
Cash, equivalents, and marketable securities totaled $268.3M at June 30, 2026. Management expects this to fund operations into 2028.
-
Key Data Readouts This Summer
Topline data from the Phase 2a trial of SION-719 (add-on to standard of care) and the Phase 1 dual combination trial of SION-451 are expected in summer 2026.
-
$250M ATM Program Established
In March 2026, the company entered into a sales agreement for an at-the-market equity program of up to $250M. No shares have been sold as of June 30, 2026.
Analysis · SION · Life Sciences
Sionna's Q2 2026 net loss grew to $29.9 million from $18.1 million a year ago, driven by higher R&D spending as its NBD1 stabilizer programs advance. The company ended the quarter with $268.3 million in cash and securities, which management says funds operations into 2028. Two critical clinical readouts are expected this summer: Phase 2a data for SION-719 as an add-on to standard of care, and Phase 1 data for SION-451 in dual combinations. The company also disclosed a $250 million at-the-market equity program established in March, though no shares have been sold. The combination of a widening loss, a large but untapped ATM overhang, and near-term binary catalysts makes this a pivotal quarter for the stock.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 29.1% of the 1683 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.32%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SION was trading at $47.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $16.48 to $51.91. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.